Objective:
To explore whether cell and gene therapy is transitioning from scientific promise to a more mature, commercially focused phase.
Approach:
- Event Coverage: Filmed at ASGCT 2026 in Boston, featuring discussions with industry leaders.
- Expert Insights: Insights from various experts in the field regarding regulatory expectations, manufacturing, and commercialization.
Key Findings:
- Emphasis on regulatory expectations and manufacturing scalability.
- Focus on cost of goods and supply-chain resilience.
- Importance of patient access and portfolio prioritization.
- Strategies for expanding therapies beyond rare diseases.
Interpretation:
Investment decisions, platform technologies, and collaboration are critical for the future of advanced therapies.
Conclusion:
The discussion highlights the evolving landscape of cell and gene therapy towards broader commercial viability.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
